1. Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatmentResearch in context
- Author
-
Luca Arcaini, Côme Bommier, Juan Pablo Alderuccio, Michele Merli, Nicole Fabbri, Maria Elena Nizzoli, Matthew J. Maurer, Vittoria Tarantino, Simone Ferrero, Sara Rattotti, Annalisa Talami, Roberta Murru, Arushi Khurana, Raphael Mwangi, Marina Deodato, Emanuele Cencini, Francesca Re, Carlo Visco, Andrew L. Feldman, Brian K. Link, Marcia Torresan Delamain, Michele Spina, Ombretta Annibali, Alessandro Pulsoni, Andrés J.M. Ferreri, Caterina Cecilia Stelitano, Elsa Pennese, Thomas M. Habermann, Luigi Marcheselli, Sunwoo Han, Isildinha M. Reis, Marco Paulli, Izidore S. Lossos, James R. Cerhan, and Stefano Luminari
- Subjects
Marginal zone lymphoma ,Prognosis ,Medicine (General) ,R5-920 - Abstract
Summary: Background: Marginal zone lymphomas (MZL), comprised of three unique but related subtypes, lack a unifying prognostic score applicable to all the patients in need for systemic chemotherapy and/or immunotherapy. Methods: Patients from the prospective NF10 study (NCT02904577) with newly diagnosed MZL and receiving frontline systemic therapy at diagnosis or after observation were used to train a prognostic model. The primary endpoint was progression-free survival (PFS) from start of treatment. The model was externally validated in a pooled analysis of two independent cohorts from the University of Iowa and Mayo Clinic Molecular Epidemiology Resource and the University of Miami. Findings: We identified 501 eligible patients. After multivariable modeling, lactate dehydrogenase (LDH) above upper normal limit, hemoglobin
- Published
- 2024
- Full Text
- View/download PDF